Table 1.
Model parameters for PFS and OS.
| Parameters | Survival model | Scale (λ), mean (SE) | Shape (γ), mean (SE) |
|---|---|---|---|
| All patients with HER2-low expression | |||
| OS in T-DXd arm | Log-logistic | 0.001587 (0.000255) | 1.828101 (0.047070) |
| OS in chemotherapy arm | Log-logistic | 0.0025756 (0.0002408) | 1.8751531 (0.0294554) |
| PFS in T-DXd arm | Weibull | 0.033803 (0.002543) | 1.119846 (0.024569) |
| PFS in chemotherapy arm | Weibull | 0.098228 (0.005706) | 0.952198 (0.021505) |
| Subpopulation with HR-positive | |||
| OS in T-DXd arm | Log-logistic | 0.0007481 (0.0001391) | 2.0369439 (0.0541151) |
| OS in chemotherapy arm | Log-logistic | 0.0025524 (0.0003565) | 1.8279014 (0.0435941) |
| PFS in T-DXd arm | Weibull | 0.03146 (0.00235) | 1.13026 (0.02425) |
| PFS in chemotherapy arm | Weibull | 0.087882 (0.004911) | 0.995184 (0.020817) |
| Subpopulation with HR-negative | |||
| OS in T-DXd arm | Log-logistic | 0.01041 (0.00146) | 1.38053 (0.04405) |
| OS in chemotherapy arm | Log-logistic | 0.011578 (0.002321) | 1.681763 (0.070765) |
| PFS in T-DXd arm | Weibull | 0.079640 (0.007434) | 0.882769 (0.032308) |
| PFS in chemotherapy arm | Weibull | 0.19410 (0.02535) | 0.84793 (0.05647) |
HER2, human epidermal growth factor receptor 2; HR, hormone receptor; OS, overall survival; PFS, progression-free survival; SE, standard error; T-DXd, trastuzumab deruxtecan.